RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an update.

RemeGen Co., Ltd. reported a sharp rise in interim revenue to RMB5,850.2 million for the six months ended June 30, 2026, a 435.74% increase year-on-year driven by robust sales of its commercial-stage drugs telitacicept and disitamab vedotin, as well as substantial technology license income from an exclusive RC148 deal with AbbVie Inc. This performance reflects accelerating commercialization and growing global partnerships, supported by multiple Phase III milestones and new regulatory approvals in China for telitacicept indications and breakthrough therapy status for disitamab vedotin in advanced gastric and bladder cancer settings, strengthening the company’s position in autoimmune and oncology therapeutics.

Telitacicept advanced with first patient dosing in several Phase III trials in China, high-profile publication of IgA nephropathy data, and new marketing approvals and conditional approvals for Sjögren’s syndrome and IgA nephropathy, including a pre-filled syringe formulation. Disitamab vedotin gained breakthrough therapy designation from China’s CDE for a first-line HER2-high advanced gastric cancer regimen, initiated a Phase III trial in this indication, and presented updated Phase II data in HER2-expressing muscle-invasive bladder cancer at a major international oncology meeting, enhancing its clinical and regulatory momentum.

The most recent analyst rating on (HK:9995) stock is a Buy
with a HK$129.00 price target.
To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock,
see the HK:9995 Stock Forecast page.